Aclaris Therapeutics, Inc. (ACRS) Operating income 2016–2025
Aclaris Therapeutics, Inc. (ACRS) annual operating income history from SEC filings — each fiscal year as reported.
-$76.4MFY2025 · since FY2016: -$48.6M → -$76.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$76.4M | +46.2% |
| FY2024 | -$141.9M | -45.8% |
| FY2023 | -$97.4M | -8.4% |
| FY2022 | -$89.9M | -0.1% |
| FY2021 | -$89.7M | -76.2% |
| FY2020 | -$50.9M | +54.2% |
| FY2019 | -$111.1M | -31.0% |
| FY2018 | -$84.8M | -56.0% |
| FY2017 | -$54.4M | -11.9% |
| FY2016 | -$48.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Net marginACRS Gross profitACRS Gross marginACRS Operating marginACRS Operating cash flowACRS Free cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Total liabilitiesACRS Shareholders’ equityACRS overview →